Equities analysts expect Ulta Beauty Inc (NASDAQ:ULTA) to announce sales of $1.53 billion for the current fiscal quarter, according to Zacks. Ten analysts have made estimates for Ulta Beauty's earnings, with the lowest sales estimate coming in at $1.48 billion and the highest estimate coming in at $1.60 billion. Ulta Beauty reported sales of $1.68 billion in the same quarter last year, which indicates a negative year-over-year growth rate of 8.9%. The business is scheduled to announce its next earnings report on Thursday, December 3rd.
According to Zacks, analysts expect that Ulta Beauty will report full-year sales of $5.97 billion for the current year, with estimates ranging from $5.86 billion to $6.30 billion. For the next year, analysts expect that the business will report sales of $7.29 billion, with estimates ranging from $6.90 billion to $7.66 billion. Zacks' sales averages are a mean average based on a survey of research analysts that follow Ulta Beauty.
Ulta Beauty (NASDAQ:ULTA) last issued its earnings results on Thursday, August 27th. The specialty retailer reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.63. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.24 billion. Ulta Beauty had a return on equity of 18.00% and a net margin of 4.41%. The firm's quarterly revenue was down 28.0% on a year-over-year basis. During the same quarter last year, the company earned $2.76 EPS.
A number of analysts have issued reports on ULTA shares. Piper Sandler lifted their price objective on Ulta Beauty from $268.00 to $275.00 and gave the stock an "overweight" rating in a research note on Friday, August 28th. JPMorgan Chase & Co. reduced their price objective on Ulta Beauty from $269.00 to $244.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 25th. Goldman Sachs Group lifted their price objective on Ulta Beauty from $257.00 to $272.00 and gave the stock a "buy" rating in a research note on Friday, August 28th. Bank of America started coverage on Ulta Beauty in a research note on Wednesday, August 12th. They issued a "neutral" rating and a $230.00 price objective on the stock. Finally, Barclays lifted their price objective on Ulta Beauty from $276.00 to $300.00 and gave the stock an "overweight" rating in a research note on Friday, August 28th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and seventeen have assigned a buy rating to the stock. The stock has an average rating of "Buy" and an average target price of $253.07.
Shares of ULTA opened at $235.45 on Tuesday. The company has a current ratio of 2.64, a quick ratio of 1.35 and a debt-to-equity ratio of 0.45. Ulta Beauty has a 12-month low of $124.05 and a 12-month high of $304.65. The business's 50 day moving average is $231.93 and its 200 day moving average is $216.61. The company has a market capitalization of $13.26 billion, a PE ratio of 48.15, a price-to-earnings-growth ratio of 4.01 and a beta of 1.49.
In related news, Director Catherine Ann Halligan sold 250 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $230.00, for a total transaction of $57,500.00. Following the transaction, the director now directly owns 2,500 shares of the company's stock, valued at approximately $575,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lorna Nagler sold 3,000 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $240.94, for a total value of $722,820.00. Following the transaction, the director now directly owns 9,963 shares in the company, valued at $2,400,485.22. The disclosure for this sale can be found here. Insiders own 4.70% of the company's stock.
A number of large investors have recently made changes to their positions in the stock. Alecta Pensionsforsakring Omsesidigt increased its position in Ulta Beauty by 28.4% during the 3rd quarter. Alecta Pensionsforsakring Omsesidigt now owns 1,288,605 shares of the specialty retailer's stock valued at $288,300,000 after buying an additional 285,000 shares in the last quarter. Nuveen Asset Management LLC increased its position in Ulta Beauty by 185.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 741,394 shares of the specialty retailer's stock valued at $150,814,000 after buying an additional 481,947 shares in the last quarter. William Blair Investment Management LLC grew its stake in Ulta Beauty by 138.8% during the 2nd quarter. William Blair Investment Management LLC now owns 651,371 shares of the specialty retailer's stock valued at $132,502,000 after purchasing an additional 378,588 shares during the last quarter. NN Investment Partners Holdings N.V. grew its stake in Ulta Beauty by 5.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 617,753 shares of the specialty retailer's stock valued at $125,663,000 after purchasing an additional 30,940 shares during the last quarter. Finally, Waddell & Reed Financial Inc. grew its stake in Ulta Beauty by 12.0% during the 1st quarter. Waddell & Reed Financial Inc. now owns 507,849 shares of the specialty retailer's stock valued at $89,229,000 after purchasing an additional 54,424 shares during the last quarter. 85.99% of the stock is currently owned by institutional investors.
About Ulta Beauty
Ulta Beauty, Inc operates as a beauty retailer in the United States. The company's stores offer cosmetics, fragrances, skincare and haircare products, bath and body products, and salon styling tools; salon services, including hair, skin, makeup, and brow services; and others, including nail products and accessories.
Recommended Story: What is the Beige Book?
Get a free copy of the Zacks research report on Ulta Beauty (ULTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Healthcare Stocks that Analysts Love
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems, and other healthcare stocks, it can be hard to identify which healthcare companies will outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same healthcare stock.
This slide show lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Healthcare Stocks that Analysts Love".